The publication in Blood provides peer-reviewed validation of the combination data, but the stock has historically shown muted reactions to clinical updates (T+20 avg alpha +0.22%). Watch for KOMET-017 Phase 3 data readouts and potential FDA filing for the combination regimen as the next catalysts.
Price Chart
Executive Summary
Kura Oncology announced publication in Blood of updated Phase 1a/b KOMET-007 data for ziftomenib + venetoclax + azacitidine in relapsed/refractory NPM1-mutated AML. In venetoclax-naïve patients at the 600 mg dose, the combination showed a 70% CRc rate, 75% central MRD negativity, and median OS not reached after 10.7 months follow-up. The data strengthen the case for ziftomenib as a combination backbone, but the stock has historically not moved significantly on similar clinical updates (T+20 avg alpha +0.22% over last 5 settled reports).
Key Facts
- 87% ORR and 70% CRc in venetoclax-naïve R/R NPM1-m AML patients at 600 mg ziftomenib dose
- 75% central MRD negativity (<0.01% threshold) in CRc responders with no prior venetoclax
- Median CRc duration 9.2 months; median OS not reached after 10.7 months follow-up in venetoclax-naïve
- 48% ORR and 24% CRc in venetoclax-experienced patients at 600 mg dose
- Low rates of differentiation syndrome (3%) and QTc prolongation (1 case) observed
- Ziftomenib (KOMZIFTI) is FDA-approved as monotherapy for R/R NPM1-m AML
- KOMET-017 Phase 3 trials in newly diagnosed NPM1-m and KMT2A-r AML are ongoing
Financial Impact
No financial figures provided in press release; clinical data supports potential label expansion into combination therapy, which could expand addressable market beyond monotherapy
Risk Factors
- Combination regimen is investigational and not yet FDA-approved
- Differentiation syndrome boxed warning remains a safety concern
- Competition from other menin inhibitors (e.g., Syndax's revumenib) could limit market share
- Phase 3 trials may fail to replicate Phase 1b results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305195 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access